Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PulsenmorePLSM -6.70%25 14-Day RSI is 41.36 as of Jul. 13, 2026. GuruFocus rates PLSM with a GF Score™ of 25/100 and a GF Value™ of $8.16 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 868 Medical Devices & Instruments companies, Pulsenmore ranks better than 69.47% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-13), Pulsenmore's 14-Day RSI is 41.36.
The industry rank for Pulsenmore's 14-Day RSI or its related term are showing as below:
PLSM's 14-Day RSI is ranked better than 69.47% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 47.695
vs PLSM: 41.36
Pulsenmore (NAS:PLSM) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Pulsenmore 14-Day RSI Related Terms
PLSM vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Pulsenmore's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulsenmore 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulsenmore's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Pulsenmore's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulsenmore (PLSM) has a 14-Day RSI of 41.36 as of Jul. 13, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Pulsenmore and its competitors. According to the industry distribution chart, Pulsenmore ranks #265 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Pulsenmore's 14-Day RSI too high?
Pulsenmore's current 14-Day RSI is 41.36. The Medical Devices & Instruments industry median 14-Day RSI is 47.70. Pulsenmore's value of 41.36 is 13.3% below this industry median. Based on the distribution chart, Pulsenmore ranks #265 out of 868 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pulsenmore has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulsenmore's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Pulsenmore ranks #265 out of 868 companies for 14-Day RSI. This puts Pulsenmore in the upper half of its industry. The industry median 14-Day RSI is 47.70. Pulsenmore's value of 41.36 is 13.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.70, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulsenmore's current 14-Day RSI of 41.36 is 13.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Pulsenmore and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulsenmore's current 14-Day RSI is 41.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulsenmore stock overvalued right now?
Based on GuruFocus' analysis, Pulsenmore (PLSM) is currently considered Possible Value Trap. The stock's GF Value™ is $8.16, compared to a current price of $3.60 — trading 55.9% below its estimated fair value. The current 14-Day RSI is 41.36 and 13.3% below the Medical Devices & Instruments industry median of 47.70. Pulsenmore's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Pulsenmore (PLSM), the current 14-Day RSI is 41.36 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulsenmore (PLSM) Overvalued in 2026?
Based on GuruFocus' analysis, Pulsenmore stock appears to be undervalued.
The current stock price of $3.60 is trading 55.9% below its estimated GF Value™ of $8.16.
GuruFocus considers Pulsenmore to be Possible Value Trap.
Key valuation signals for PLSM:
14-Day RSI: 41.36
GF Value™: $8.16 vs. price of $3.60 (55.9% below fair value)
Industry Position: 13.3% below the Medical Devices & Instruments median (#265 of 868)
No single metric tells the full story. See the PLSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
25GF Score
Get the complete analysis for PLSM
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSM has been successfully added to your 
